Hypotensive lipid-containing biodegradable intraocular implants and related methods
AssigneeAllergan, Inc.
InventorPatrick M. Hughes
Life of this patent
Estimating the term…
Abstract
Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
Claims11
-48. (canceled)
A method of treating an ocular condition, comprising the step of placing a biodegradable intraocular implant in an ocular region of the eye, the implant comprising travoprost and a biodegradable polymer matrix that releases an amount of the travoprost from the implant effective to reduce at least one symptom of the ocular condition, wherein the implant is a rod or filament, and wherein the amount of the travoprost is released into the eye for a period of time greater than about one week to less than about six months after the implant is placed in the ocular region of the eye.
-55. (canceled)
A method of treating an ocular condition, comprising the step of placing a biodegradable intraocular implant in the anterior chamber of the eye, the implant comprising travoprost and a biodegradable polymer matrix comprising a polylactic acid polymer that releases an amount of the travoprost from the implant effective to reduce at least one symptom of the ocular condition, wherein the implant is a rod or filament, and wherein an amount of the travoprost is released into the eye for a period of time greater than about one week to less than about six months after the implant is placed in the anterior chamber of the eye.
Dependencies are inferred from the claim text.